Development of rifapentine: The way ahead

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 8, 1998, Pages 612-615

  Mitchison, D A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

BACTERICIDAL ACTIVITY; CLINICAL PROTOCOL; DRUG BIOAVAILABILITY; DRUG INDUSTRY; GOOD MANUFACTURING PRACTICE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SIDE EFFECT; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CHINA; CLINICAL TRIALS; DRUG INDUSTRY; HONG KONG; HUMANS; RECURRENCE; RIFAMPIN; TUBERCULOSIS;

EID: 0031856542     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Tam C M, Chan S L, Lam C W, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med 1998; 157: 1726-1733.
2. Tam C M, Chan S L, Lam C W, Dickinson J M, Mitchison D A. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997; 1: 411-416.
3. Kanyok T. A lesson to be learned. Int J Tuberc Lung Dis 1997; 1: 490-492.
4. O'Brien R J, Vernon A A. New tuberculosis drug development: how can we do better? Am J Respir Crit Care Med 1998; 157: 1705-1707.
5. Fox W. The problem of self-administration of drugs: with particular reference to pulmonary tuberculosis. Tubercle 1958; 39: 269.
6. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ 1970; 43: 143-206.
7. Tuberculosis Research Centre, Madras. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis - A controlled trial of four regimens. Tubercle 1981; 62: 13-29.
8. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Lancet 1975; 2: 1105-1109.
9. Truffot-Pernot C, Grosset J, Bismuth R, Lecoeur H. Activité de la rifampicine administrée de manière intermittente et de la cyclopentyl rifamycine (ou DL473) sur la tuberculose expérimentale de la souris. Rev Fr Mal Respir 1983; 11: 875-882.
10. Dhillon J, Dickinson J M, Gay J A, Ng T K, Mitchison D A. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tubercle Lung Dis 1992; 73: 116-123.
11. Yan Biya, Li Zhen, Feng Ying. A clinical comparative study of Chinese-made rifapentine on chemotherapy of tuberculosis (follow-up results after 3 years), National Cooperative Group on the Clinical Study of Rifapentine. Chinese J Antibiot 1992; 7: 313-322.
12. Chan S L, Yew W W, Porter J H D, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994; 3: 267-274.
13. Taglietti M, Frigo G M, Cavenaghi L, Buniva G. Pharmacokinetics of rifapentine in healthy volunteers. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 23- 26 October 1988, Los Angeles, CA, USA.
14. Sirgel F A, Botha F J H, Parkin D P, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts. A new method of drug assessment. J Antimicrob Chemother 1993; 32: 867-875.
15. Donald P R, Sirgel F A, Botha F J, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 895-900.
16. Long M W, Snider D E, Farer L S. US Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 879-894.
17. Mitchison D A, Sturm W A. The measurement of early bactericidal activity. In: A Malin and K P W J McAdam, eds. Bailliere's Clinical Infectious Diseases: Mycobacterial Diseases Part II. London; Bailliere Tindall, 1997: pp 185-206.